Organization

National Cancer Center Singapore

2 abstracts

2 posters

Poster

First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

Poster

First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

Abstract

Delineating histomorphological signatures of iCMS subtypes in colorectal cancer using multiplexed fluorescence-in-situ hybridization.

Org: Genome Institute of Singapore, National Cancer Center Singapore, National Cancer Centre of Singapore,

Abstract

Retrieval-augmented large language models for clinical trial screening.

Org: Memorial Sloan Kettering Cancer Center, National University of Singapore, National Cancer Centre Singapore, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,